Diabetes Product-Value: Stakeholders Changing Expectations and the Role of Real-World Evidence
|
|
- Horatio Kennedy
- 8 years ago
- Views:
Transcription
1 Diabetes Product-Value: Stakeholders Changing Expectations and the Role of Real-World Evidence Dr. Anthony Abruzzini Karen Fraser Dr. Frederick Gale Copyright 2013 Quintiles
2 Today s Presenters Dr. Anthony Abruzzini Vice President, Global Strategic Drug Development Dr. Abruzzini has 3 years of drug discovery and animal research experience, 6 years of entrepreneurial biotechnology company experience in clinical development and regulatory affairs, and 18 years of CRO experience in regulatory affairs, clinical development, and project management, including 15 years at Quintiles. In his current role, he provides strategic guidance to partner companies in the planning and design of development pathways for new drugs and biologics. His responsibilities include development of registration strategies for new drug and biologics license applications (NDAs, BLAs, MAAs, etc.). Karen Fraser Vice President, Global Marketing and Brand Solutions Ms. Fraser has over 25 years experience in the industry, with expertise in commercial brand marketing. Prior to joining Quintiles 12 years ago, she was responsible for a number of industry brands in different therapy areas, before going on to establish and run a profitable marketing consultancy, introducing the concept of outsourced brand management and successfully co-ordinating the UK launch of 4 brands for 3 international companies. During her time at Quintiles, she has provided marketing insight and support to many partnership opportunities spanning the US, UK, Europe and the Far East in numerous therapeutic areas. Dr. Frederick Gale, MD, FACS Vice President and Medical Director, Real-World and Late Phase Research Dr. Gale has 25 years of experience in consulting support for the biopharma and biotech industries, including strategic research on the many drivers underlying decision-making behaviors of healthcare stakeholders. In his current role, he leverages that experience to advise on evidence optimization, in order for results to be compelling to the decision-makers that lie beyond regulatory approval. Frederick trained in the subspecialty of Infectious Diseases, is Board certified in General Surgery, and has won awards for teaching excellence in both of these disciplines. He is a Fellow of the American College of Surgeons, and serves on the Value Proposition team of Quintiles Center of Excellence in Diabetes.. Quintiles Confidential 2
3 Overview Diabetes drug development environment Evolving expectations of regulators, prescribers, patients, and payers Case examples Preview of future trends 3
4 Today s Webinar Audience 4% 6% 24% Academia Biostatistician Clinical Operations 3% 4% 35% Epidemiology Health Economics/Health Outcomes Medical Affairs 7% Market Access Regulatory Affairs 8% 9% Other 4
5 Polling Questions A small number of polling questions have been added to today s webinar to make the session more interactive? 5
6 Diabetes Drug Development Environment 6
7 Diabetes: The Global Burden Environment for Diabetes Drug Development, by the numbers Worldwide > 366 million people had diabetes in 2011* > 552 million people are expected to have diabetes by 2030 > 50% are undiagnosed > 78,000 children develop type 1 diabetes every year > 4.6 million deaths resulted from diabetes in 2011** > Diabetes caused > 465 B USD healthcare expenditures in 2011 * 80% with diabetes live in low- and middle-income countries ** WHO projects diabetes will be the 7 th leading cause of death in 2030 United States > 25 million people had diabetes in 2011 > 33 million people are expected to have diabetes by 2030 > 27% are undiagnosed > 1/400 children (<20 y) have type 1 diabetes > 180,000 million deaths resulted from diabetes in 2011 > Diabetes caused > 176 B USD healthcare expenditures in 2011 (6,800 USD diabetes related expenditure per person with diabetes) 7
8 Success Rates by Phase Bunnage ME: Nature Chemical Biology 7: ,
9 Diabetes Research Today IMPACT Over 230 drugs in clinical development for treatment of diabetes and related conditions This growing pipeline is driving initiation of many large and complex phase II and Phase III trials The sheer number of drugs in development requires higher efficiency in the conduct of clinical trials Diabetes epidemic drives a critical need to focus on product value Source: 2012 Phrma Medicines in Development for Diabetes Report 9
10 Unique Challenges in Diabetes Drug Development Diabetes Phase 3 programs have 2 discrete goals > Demonstration of glycemic efficacy: Clinical program typically requires 3,000 4,500 patients > Demonstration of cardiovascular safety: CV Outcome Study (CVOT) typically requires 4,500 10,000 patients Regulatory guidance for demonstration of CV Safety: US & EU > Guidance for Industry: Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), December 2008 > Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, 14 May 2012 In order to satisfy FDA 2008 requirements > Time: Typically 3-5 years (additional) > Cost: ~ $200M to $350M higher than prior FDA CV safety requirement 10
11 Challenges in Demonstrating Cardiovascular Safety 11
12 CVO Trial Landscape: Populations and MACE Definitions MACE-primary endpoint Start Drug Size Population NCT ORIGIN CV mort 9/2003 Insulin Glargine 12,500 At risk CVD prior MI,stroke, revasc TECOS (M4) UA-hosp 12/2008 Sitagliptin 14,000 Preexisting CV D ACE (M3) 02/2009 Acarbose 7,500 Prev MI, ACS, UA, stable Angina EXAMINE (M3) 09/2009 Alogliptin 5,400 ACS within 15 to 90 days CANVAS (M3) 11/2009 Canagliflozin 4,300 History of or a high risk CVD AleCardio (M3) 02/2010 Aleglitazar 7,000 ACS 2-6 w prior to randomization SAVOR TIMI-53 (M3) 04/2010 Saxagliptin 16,500 EstablCVD and/or multiple RF ELIXA (M4) UA-hosp 06/2010 Lixisenatide 6,000 ACS within 180 days EXSCEL (ND) 06/2010 Exenatide LAR 9,500 No CV Inclusion listed C-SCADE 8 (M3) 07/2010 Empagliflozin 7,000 Prior MI, UA, revasc CAROLINA (M4) UA-hosp 10/2010 Linagliptin 6,000 Pre-existing CVD LEADER (M3) 11/2010 Liraglutide 8,750 Concomitant CVD REWIND (M3) 07/2011 Dulaglutide 9,600 Established CVD ITCA 650 (M4) UA-hosp 01/2012 Exenatide ITCA650 2,000 Hx of CVD, Stroke or PAD Selected populations vary, as does MACE definition Adapted from Gore O, McGuire D. Diabetes & Vascular Disease Research. 9(2)
13 CVOT Endpoint Considerations MACE or MACE+? MACE (CV Mortality, MI, Stroke) > Attainment of a given level of statistical significance is afforded more gravitas than MACE + > Accruing sufficient events will be more challenging than MACE+ > MACE+ > Inclusion of revascularization has value to clinicians as reason to use > Unstable angina may require core-lab validation of angiography > Hospitalization for Acute Coronary Syndrome FAVORED POSITION > Dependent on MOA of drug candidate and concurrence with regulatory authorities RESULT(S) > Trade-off on time-tocompletion of CVOT versus evaluation on target patient population for marketed product 13
14 CVOT Design Considerations Non-Inferiority versus Superiority Designs Non-inferiority [NI] > Risk Ratio: <1.8 pre-nda and <1.3 post NDA (2-sided, 95% CI) > Meta-analysis or stand-alone study > Precedents for MACE, or MACE+ exists Superiority [S] > Risk Ratio: <1.0 > Stand-alone study > Ability of sponsor to propose MACE+ is desired FAVORED POSITION > [NI] satisfies regulatory requirements, but requires more subject events > [S] may be difficult to demonstrate in target population 14
15 Polling Questions What is your experience in conducting cardiovascular outcomes studies for antidiabetic drugs?? >No experience >1 study >2 or more studies Quintiles Confidential 15
16 Diabetes Insights KOLs / Primary Care Clinicians / Patients 16
17 Insulin + GLP-1 Insulin FFAR1 / GPR40 agonist SGLT-2 GLP-1 PPAR DPP-4 The diabetes pipeline is extremely crowded Alogliptin (Takeda) Alogliptin+ Metformin (Takeda) Alogliptin+ Pioglitazone (Takeda) Omarigliptin MK-3102 (Merck) Melogliptin (Glenmark) Aleglitazar (Roche) KRP-104 (Kyorin) Lixisenatide (Sanofi) Dulaglutide (Lilly) Albiglutide (GSK) Semaglutide (Novo Nordisk) LLX4211 Lexicon Forxiga (BMS / AZ) Canagliflozin (J&J) Dapagliflozin + Metformin (BMS / AZ) Empagliflozin (BIL) Canagliflozin + Metformin (J&J) Empagliflozin +Linagliptin (BIL) Fasiglifam (TAK-875) (Takeda) Empagliflozin +Linagliptin (BIL) BI 4487 BIL Tofogliflozin Chugai PF Pfizer TS-071 Taisho ISIS-SGLT2RX - Isis Ryzodeg (Novo Nordisk) Degludec (Novo Nordisk) LY (Lilly / BI) U300 New Lantus (Sanofi) LY (Lilly) IDegLira Degludec + Victoza (Novo Nordisk) LixiLan Lantus+ Lyxumia (Sanofi) Launched in some EU markets 17
18 Pipeline Marketed KOL Insights*: Newer classes in diabetes DPPIVs have high utility and are seen as extremely safe, no hypos, weight neutral but have only moderate efficacy (eg sitagliptin, vildagliptin, saxagliptin) > Used post metformin and instead of /after sulphonylureas > Class seen as similar - many choices but sitagliptin continues to dominate GLP1s are effective, no hypoglycaemia, cause weight loss (eg exenatide, liraglutide) > Used pre insulin (or earlier in obese patients) cost and route of administration limit use > Main differences are dosing/formulations Byetta (BD), Victoza (OD) and Bydureon (OW) SGLT-2s are seen as an important new class by KOLs (eg dapagliflozin, canagliflozin) > Important new class with attractive and novel mode of action, independent of insulin > Moderate reduction in HbA1c (~1.1%), weight loss - seen as a potential challenge to the DPP-IV class > High levels of thrush/uti in female patients may limit Newer Insulins (eg degludec/tresiba) > Tresiba rejected by FDA - require CV outcomes studies > Truly flat profile very attractive - additional benefit vs Lantus tbd > Benefit in reducing nocturnal hypoglycaemia > Sanofi s Lixilan (lixisenatide/lantus) may compete directly as there is a high level of confidence with Lantus PPAR α/γ co-agonist s profile similar to the glitazones (eg aleglitazar, Roche) > Effective HbA1c reduction, no hypoglycaemia, HDL increase,tg reduction > S/E s incl weight increase, oedema, fractures, CHF, BP, > Two dual PPARs discontinued in late clinical development * KOL qualitative interviews conducted with 8 specialists in Germany, Italy, Spain & UK 18
19 Primary Care Insights* Diabetes is a significant & increasing workload The Classic New Patient Frequency of HbA1c Measurement Age: yrs Employed HbA1c = 7-9% BMI = % 36% 1x per year 2x per year 4 x per Year 12x per year Burden of T2D in primary care is growing Consultation patterns > Almost 80% GPs say T2D patients are now presenting younger > Half of GPs say the number of new T2D patients has increased in the last year > 86% believe the aging population and increasing obesity will result in a dramatic rise in T2D patients Genuine concerns for T2D patients > 80% of GPs are very concerned for the future of their diabetic patients unless they take more responsibility for their condition > 70% of GPs require patients to re-present following routine HbA1c tests Support would be welcomed > Improved communication and support amongst the care team would be of high value to GPs > Better patient support & education is desirable > Improved patient compliance is a genuine need > Over 30% of GPs consider an remote monitoring system would be appropriate in T2D * GP online survey conducted in France, Germany, Italy, Spain & UK (n=75) 19
20 Primary Care Insights* Treatment & Management National Guidelines are viewed as most important and useful > Local Guidelines also important > A greater emphasis on individual patient type targets would be helpful Metformin, is the clear 1 st line choice for newly diagnosed patients > DPP- IVs are becoming the established the 2 nd line add-on therapy > The GLP-1s are increasingly the 3 rd line choice > The addition of a 2 nd therapy is often within 24 months of diagnosis The GP involves a variety of other specialities in the care of T2D patients > Key specialities included are Practice Nurses, Diabetologists, Ophthalmologists and Chiropodists - Trigger for referral to 2 Care is usually lack of HbA1c control - Ophthalmologists and Chiropodists generally included when complications arise > Most GP s see themselves as having the greatest impact on treatment Relatively high awareness exists of the new / emerging treatments > ~ 30% of GPs are aware of the new SGLT-2 drugs in the pipeline > Real concerns about future cost of effectively managing Diabetes population * GP online survey conducted in France, Germany, Italy, Spain & UK (n=75) 20
21 Patient Insights* Disease views Most patients do believe their condition is serious Many patients are taking > 1 medication 7% 65% Extremely serious Serious No feeling either way A little serious Not at all serious 100% 80% 60% 40% 20% 0% 89% 64% Taking medication More than one medication Patients have a fatalistic view of their condition > Patients have discussed the risk of complications with their GP > Approx 30% have been warned of the risk of premature death > There is a strong sense of resignation Additional Insights Most patients: > were aware of Diabetes and how common it is prior to their diagnosis > had not been warned about potentially developing diabetes > feel they have acted on dietary and lifestyle advice given on diagnosis > are asked to take a regular reading of their blood sugar levels * Patient online market research conducted in France, Germany, Spain & UK (n=114) 21
22 The diabetes patient is complicated Remote monitoring would be welcomed Quarterly HCP visits is usual Over 30% feel it will impact on ability to work in future Breaking established patterns of behaviour (i.e. the potential background causes to the disease) is inherently difficult As with many chronic conditions, in the absence of life impacting symptoms, the patient can remain in a state of resignation regarding the diagnosis. Compliance to treatment programmes is a major issue The patient can be living with the condition for as long 10 years before diagnosis It has been established that people with diabetes often have inadequate knowledge of their condition, risk factors and associated complications Many believe Diabetes is Hereditary with Lifestyle contributors Preferred Info sources: Internet Pharmacists Other HCPs Patients have insight into their own impact on course of disease 22
23 Polling Question Which Diabetes patient focused activities do you think is most important for the future?? Diet & Lifestyle Education Self Help Groups Patient Adherence Programmes Monitoring and PRO Collection 23
24 Payer Perspective 24
25 Payer Highlights for Diabetes HTA Watch: reports and analysis from 90 agencies in 32 countries In a recent six-month period, over 40 HTA reports published for diabetes: Diabetes HTAs per Country in 6 Months Most Common Reasons for Rejection Less than 1 yr follow-up No compelling data on incremental benefits vs SOC (e.g., weight loss, lipids) No controlled studies v. SOC Insufficient economic data 0 Insufficient QOL data 25
26 Principles and Case Studies for Real World and Late Phase Study Design 26
27 Late Phase Interventional Trials: Challenges and take-home principles from across several studies Recurring Challenges Temptations for maximizing power at the expense of being less compelling to decision-makers: o Excluding non-compliant patients; giving special attention to those remaining o Stipulating highly restrictive exclusion criteria in efficacy studies o Stipulating highly restrictive inclusion criteria in safety studies Decision-maker assumptions can differ from those of the manufacturing team s about: o Unmet needs (e.g., hypoglycemia) o A compound s comparative strengths Stakeholder demands for economic evaluation (e.g., CVZ, NICE, PBAC, and SMC) Deliver new products that not only appear to be safe, but are safe Delivering Stakeholder-Oriented Results Plan for later phase randomized trials to be as naturalistic as possible real-world interventional Learn stakeholders priorities for a compelling value-story o Discuss optimal thresholds for patient inclusion / exclusion o Instead of excluding data in a way that sacrifices real-world projectability, consider sub-analysis and stratification o Consider a sampling plan that includes un- and under-studied patients (elderly, renal insufficient, AA, pediatric) o Consider fielding tandem studies from the same protocol o Ask what they see as the unmet needs in diabetes within their healthcare system o Ask their perceptions about relative strengths / weaknesses of products and categories o Get help understanding the economic evidence demands of all intended markets Run ROI analysis to guide evidence optimization First, make the most out of pre-marketing safety data: interrogate multiple safety analysis datasets Learn from diabetes Clinical Project Managers 27
28 Case Study: DM in Primary Care Evolving landscape of North American treatment patterns of HCPs initiating diabetes care Challenges Clarify Practice Patterns/Outcomes in NA Clarify care patterns at sites initiating Rx for T2D Describe referral patterns, and care at those sites Relate practice and referral patterns to outcomes 10,000 patients, 388 sites, North America PIs are frontline PCPs, not trialists Deliver meaningful comparisons across settings and over time Solution Handling Operations and Data Issues De-identification of study data through tokens Single-site submission to central IRB; waiver of formal informed consent EMRs identify patients per inclusion criteria, and invite patient directly Patients self-register and give Authorization to Participate; EMR pre-populates database Data supplemented by site surveys, patient surveys, and per visit clinician thinking Timeline Overview 1 year 18 months to 4 years Baseline epro & HRU 1 y 2 y 3 y 4 y 28
29 Staggered Enrollment Allows observation of practice patterns over time 12 months FPI LPI Study End 30 months 18 months 48 months 29
30 Sources of Insights Site, physician, and patient characteristics; patient observations; medications, labs, and special exams; clinical decision-making; and outcomes 2 EMR Data Merges directly with patient survey data 1 Survey Data o Patient o Site Admin o HCP 3 Clinical Reasoning Sites enter rationale for med changes & referrals Data Warehouse 30
31 Preview of Future in Diabetes Diabetes product-value trends Increasing emphasis on evidentiary sufficiency, including real-world value > Better comparisons to SOC > Longer-term follow-up > Deeper analysis of all safety data > More pediatric trials in T2D > Use of anti-diabetic agents for pre-diabetes > Metabolic surgery; diabetes remission > The need to develop ethical excellence in recruiting indigent and low-literacy patients Increased investment in digital and nurse-led patient education and support Potential game-changers > Proof of macrovascular end-organ protection in T2D > Beta cell preservation or restoration 31
32 Conclusion: multiple drivers for increased efficiency and evidence-value in diabetes Diabetes prevalence greatly increasing globally The pipeline is crowded Payers, providers, and patients are all under pressure to make good decisions they now join regulators as empowered decision-makers For both efficiency and sufficiency of evidence, their voices must be sought early and often, leading to the idea of late phase thinking, starting early Giving stakeholders the evidence support they need means evolving from traditional clinical development planning to product-value planning A product s real-world performance helps define its real-world value 32
33 Upcoming Events Upcoming Webinar Title: AHRQ Registry of Patient Registries (RoPR): An Introduction Date: July 23, 2013, 11am-12pm EDT Register: 33
How To Get Better Health Care
Kardiovaskulär säkerhet vid behandling av typ 2-diabetes Vad säger senaste data? Michael Alvarsson Kliniken för Endokrinologi, Metabolism och Diabetes Karolinska Universitetssjukhuset Solna Near-normal
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationUnderstanding Diseases and Treatments with Canadian Real-world Evidence
Understanding Diseases and Treatments with Canadian Real-world Evidence Real-World Evidence for Successful Market Access WHITEPAPER REAL-WORLD EVIDENCE Generating real-world evidence requires the right
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationType 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationDiabetes in Primary Care course MCQ Answers 2016
Diabetes in Primary Care course MCQ Answers 2016 Diagnosis of Diabetes HbA1C should not be used as a diagnostic tool in the following situations: (answer each TRUE or FALSE) 1. Gestational Diabetes TRUE
More informationAnalyzing the Global Diabetes Market 2016
Brochure More information from http://www.researchandmarkets.com/reports/2060216/ Analyzing the Global Diabetes Market 2016 Description: Diabetes is a chronic disease in which there are high levels of
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationThe type 2 diabetes market is undergoing a paradigm
Elsevier Business Intelligence PRESCRIPTION PHARMACEUTICALS AND BIOTECHNOLOGY July 16, 2012 Founded 1939 In A Changing Diabetes Drug Market, Who Will Come Out On Top? Jessica Merrill j.merrill@elsevier.com
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationDIABETES DISEASE MANAGEMENT PROGRAM DESCRIPTION FY11 FY12
DIABETES DISEASE MANAGEMENT PROGRAM DESCRIPTION FY11 FY12 TABLE OF CONTENTS 1. INTRODUCTION.3 2. SCOPE........3 3. PROGRAM STRUCTURE...4 3.1. General Educational Interventions.....4 3.2. Identification
More informationPrescribing for Diabetes. England 2005-06 to 2013-14
Prescribing for Diabetes England 2005-06 to 2013-14 Published 12 August 2014 We are the trusted national provider of high-quality information, data and IT systems for health and social care. www.hscic.gov.uk
More informationNew FDA Guidances On Anti-Diabetes Therapies Change the Landscape of Drug Development
New FDA Guidances On Anti-Diabetes Therapies Change the Landscape of Drug Development How Quintiles Can Help You Navigate the Guidances and Successfully Develop Pipeline Drug Candidates Prepared By: John
More information4. Does your PCT provide structured education programmes for people with type 2 diabetes?
PCT Prescribing Report Drugs used in Type 2 Diabetes Discussion Points 1. Does your PCT have a strategy for prevention of type 2 diabetes? Does your PCT provide the sort of intensive multifactorial lifestyle
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationHow To Grow A Company
Profitability & Growth in 2006: Corporate Overview April 2006 Certain statements in this presentation may constitute forward looking statements within the meaning of the Private Securities Litigation Reform
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationPrescribing for Diabetes, England 2005-06 to 2012-13
Prescribing for Diabetes, England 2005-06 to 2012-13 Published 13 August 2013 This product is relevant to members of the public and other stakeholders to support the understanding of primary care prescribing
More informationInsulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020
Brochure More information from http://www.researchandmarkets.com/reports/2075322/ Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020 Description: Insulin Degludec (Type 2 Diabetes) Analysis
More informationAre insulin analogs worth their cost in type 2 diabetes?
Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology
More informationCore therapeutic areas
Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationPersonalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach
Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND
More informationNew and Emerging Diabetes Medications. What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE
New and Emerging Diabetes Medications What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE Objectives 1) Describe the clinical indications on select emerging novel diabetes
More informationSanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)
PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationNew and Future Treatments for Diabetes. Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014
New and Future Treatments for Diabetes Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014 Conflicts of interest Investigator Carmelina study of Linagliptin (Boehringer
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationType 2 Diabetes workshop notes
Group 1 notes Abi / Nicole Type 2 Diabetes workshop notes 4.1 Population The group discussed the following sub groups that may need addressing: Men-as they tend to die earlier compared with women, their
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationTYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS
TYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS The aim of the Diabetes level 2 service is to provide a high quality service for safe initiation and optimization of injectable therapy within GP networks.
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationCRT Plenary Meeting Proposed topics for future workshops and workstreams
CRT Plenary Meeting Proposed topics for future workshops and workstreams S. Schroeder Surrogate / Composite Endpoints Regulatory workshop Co-chairs: S. Anker / S. Schroeder Postponed to Q4 / 2014 Workshop
More informationPrescribing for Diabetes in England - An Update: 2002-2008 An analysis of volume, expenditure and trends
Prescribing for Diabetes in England - An Update: 2002-2008 An analysis of volume, expenditure and trends June 2009 diabetes Health Intelligence YHPHO YORKSHIRE & HUMBER PUBLIC HEALTH OBSERVATORY Diabetes
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More informationThe Burden of the Complicated Type 2 Diabetes Patient in China. White Paper
White Paper Catalysts driving successful decisions in life sciences. The Burden of the Complicated Type 2 Diabetes Patient in China by Marco DiBonaventura, Ph.D. Director, Health Economics and Outcomes
More informationThe registry of the future: Leveraging EHR and patient data to drive better outcomes
The registry of the future: Leveraging EHR and patient data to drive better outcomes Brian J. Kelly, M.D. President, Payer and Provider Solutions, Quintiles Jason Colquitt, VP, IT, Head of RWLPR IT, Global
More informationWorkshop on Patient Support and Market Research Programmes
Workshop on Patient Support and Market Research Programmes Spectrum of programmes falling under the terms of PSP and MRPs and the and the type of safety data collected Pharmaceutical Industry Associations
More informationBiogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest
Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest Cycle C June 2, 2015 1 Introduction The landscape for the treatment of relapsing Multiple Sclerosis (MS) has quickly evolved over
More informationWestern European Insulin Delivery Devices. Market M62E-52
Western European Insulin Delivery Devices Market M62E-52 Table of Contents Chapter 1 Overview and Executive Summary Overview 1-1 Introduction 1-1 Diabetes 1-1 Insulin Therapy 1-2 Insulin Delivery Devices
More informationDiabetes Care 2011-2012
Clinical Innovations in the Patient Centered Medical Home to Improve Diabetes Care Robert A. Gabbay, MD, PhD, FACP Chief Medical Officer & Senior Vice President Joslin Diabetes Center Harvard Medical School
More informationHollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationThe Patient Journey in High Resolution
The Patient Journey in High Resolution Innovating for a richer understanding of the patient journey By Jackie Ilacqua Tel +1 201-574-8079 Email jackie.ilacqua@ipsos.com 1 xx-xx-xx Achieving a rich, yet
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having bowel preparation for a flexible sigmoidoscopy or a colonoscopy or a combined gastroscopy and colonoscopy This guidance is provided to assist
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationPopulation Health Management Program
Population Health Management Program Program (formerly Disease Management) is dedicated to improving our members health and quality of life. Our Population Health Management Programs aim to improve care
More informationCara Liday, PharmD, CDE Associate Professor, Idaho State University Clinical Pharmacist and CDE, InterMountain Medical Center Pocatello, ID The planners and presenter have disclosed no conflict of interest,
More informationHealthCare Partners of Nevada. Heart Failure
HealthCare Partners of Nevada Heart Failure Disease Management Program 2010 HF DISEASE MANAGEMENT PROGRAM The HealthCare Partners of Nevada (HCPNV) offers a Disease Management program for members with
More informationShaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact
Shaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact Task Force for the National Conference on Diabetes: The Task Force is comprised of Taking Control of
More informationSlide 1. Diabetes care strategy. Lars Fruergaard Jørgensen EVP Corporate Development
Slide 1 Diabetes care strategy Lars Fruergaard Jørgensen EVP Corporate Development Diabetes care strategy Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More informationSHOULD TYPE 2 DIABETES MANAGEMENT BE MORE OF A PRIORITY IN POST-ACUTE CORONARY SYNDROME PATIENTS?
SHOULD TYPE 2 DIABETES MANAGEMENT BE MORE OF A PRIORITY IN POST-ACUTE CORONARY SYNDROME PATIENTS? This symposium took place on 14 th September 2015 as part of the 51 st Annual Meeting of the European Association
More informationType 2 Diabetes. Tabinda Dugal GP Day 4/05/16
Type 2 Diabetes Tabinda Dugal GP Day 4/05/16 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget Projections.. 5 million by 2025 Youngest patient? T2DM Type 2 diabetes
More informationGlobal Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
More informationLeveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources
Leveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources James Charnetski, Practice Leader Commercial Analytics & Effectiveness Quintiles Integrated Healthcare
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationThe Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx:
James Cromie The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx: INEFFECTIVE and UNSUSTAINED Bariatric surgery is an Effective and Durable treatment option Well established
More informationInvestor science conference call from ADA 2009 New Orleans, 8 June 2009
Investor science conference call from ADA 2009 New Orleans, 8 June 2009 Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking statements may be
More informationInitiate Atorvastatin 20mg daily
Type 2 Diabetes Patient Objectives Stopping Smoking BMI > 25 kg m² Control BP to
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationLeveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology. Presented by: Elisa Cascade, MediGuard/Quintiles
Leveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology Presented by: Elisa Cascade, MediGuard/Quintiles About Elisa Cascade, VP MediGuard/Quintiles Assisted in site
More informationDrug Treatment for Weight Loss: New Advances
Drug Treatment for Weight Loss: New Advances William G. Haynes FRCP MD Professor of Internal Medicine Divisions of Endocrinology and Cardiovascular Medicine University of Iowa Outline Why should we use
More informationGlucagon Receptor Antagonist: LGD-6972 Program Overview and Phase 1b Results
Glucagon Receptor Antagonist: LGD-6972 Program Overview and Phase 1b Results American Diabetes Association s 75th Scientific Sessions June 7, 2015 Boston 2 Safe Harbor Statement The following presentation
More informationNewer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013
Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban
More informationPEER REVIEW HISTORY ARTICLE DETAILS
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationDrug Class Review. Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Streamlined Update 1 Report June 2014 The purpose of Drug Effectiveness Review Project reports is to make available information regarding
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationMEDICAL DEVICE & DIAGNOSTICS
to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationDiabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationA Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes
A Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes 1. Summary... 1 2. Background... 2 3. Purpose 2 4. Responsibilities. 2 5. Blood Glucose Monitoring. 2 6. Resident Groups that
More informationManaging Patients with Multiple Chronic Conditions
Best Practices Managing Patients with Multiple Chronic Conditions Advocate Medical Group Case Study Organization Profile Advocate Medical Group is part of Advocate Health Care, a large, integrated, not-for-profit
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH.
ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH. ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDiabetes and stroke. What is diabetes? What are the symptoms of diabetes? Stroke Helpline: 0303 3033 100 Website: stroke.org.uk
Stroke Helpline: 0303 3033 100 Website: stroke.org.uk Diabetes and stroke Diabetes is a condition caused by too much sugar in your blood. There are over three million people in the UK who have diabetes.
More information